Clinical trial
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With…
NCT00472056 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00472056 |
|---|---|
| Title | Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies |
| Official title | Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab |
| Enrollment | 93 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | May 11, 2007 |
| Last update posted | Mar 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: